1. Home
  2. IDT vs ANAB Comparison

IDT vs ANAB Comparison

Compare IDT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDT Corporation Class B

IDT

IDT Corporation Class B

N/A

Current Price

$54.87

Market Cap

1.2B

ML Signal

N/A

ANAB

AnaptysBio Inc.

N/A

Current Price

$54.33

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDT
ANAB
Founded
1990
2005
Country
United States
United States
Employees
1925
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
IDT
ANAB
Price
$54.87
$54.33
Analyst Decision
Strong Buy
Buy
Analyst Count
1
12
Target Price
$80.00
$71.67
AVG Volume (30 Days)
123.2K
465.0K
Earning Date
06-04-2026
05-08-2026
Dividend Yield
0.55%
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$4.34
N/A
Revenue Next Year
N/A
$52.14
P/E Ratio
$15.10
N/A
Revenue Growth
N/A
157.01
52 Week Low
$45.72
$17.11
52 Week High
$71.12
$73.30

Technical Indicators

Market Signals
Indicator
IDT
ANAB
Relative Strength Index (RSI) 53.11 44.90
Support Level $50.71 $53.46
Resistance Level $58.44 $57.70
Average True Range (ATR) 1.98 2.43
MACD -0.07 0.12
Stochastic Oscillator 42.47 47.74

Price Performance

Historical Comparison
IDT
ANAB

About IDT IDT Corporation Class B

IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: